Lønning P E, Johannessen D C, Thorsen T, Ekse D
Department of Biochemical Endocrinology, University of Bergen, Norway.
J Steroid Biochem. 1989 Oct;33(4A):541-5. doi: 10.1016/0022-4731(89)90039-3.
Plasma levels of estrone and estrone sulfate were measured in 16 postmenopausal women with advanced breast cancer before and during chronic aminoglutethimide therapy. Aminoglutethimide caused a significant reduction in plasma estrone (mean 36%, P less than 0.025) and estrone sulfate (mean 65%, P less than 0.001). The estrone/estrone sulfate ratio was increased by a mean of 84% (P less than 0.0025). These results suggest that aminoglutethimide influences plasma estrone sulfate by mechanisms unrelated to aromatase inhibition. The findings in this study are consistent with previous results suggesting that aminoglutethimide treatment enhances the rate of estrone sulfate metabolism. This biochemical effect of aminoglutethimide treatment could be a contributory factor to the drugs mechanism of action.
对16名晚期乳腺癌绝经后女性在慢性氨鲁米特治疗前及治疗期间测量了血浆雌酮和硫酸雌酮水平。氨鲁米特使血浆雌酮（平均降低36%，P<0.025）和硫酸雌酮（平均降低65%，P<0.001）显著降低。雌酮/硫酸雌酮比值平均升高84%（P<0.0025）。这些结果表明，氨鲁米特通过与芳香化酶抑制无关的机制影响血浆硫酸雌酮。本研究结果与先前结果一致，表明氨鲁米特治疗可提高硫酸雌酮的代谢率。氨鲁米特治疗的这种生化效应可能是该药物作用机制的一个促成因素。
